WO2023278300A1 - Forme posologique solide de n-1-pyrrolidine-n-5-(3-trifluorométhoxy)phényl biguanide et ses utilisations - Google Patents

Forme posologique solide de n-1-pyrrolidine-n-5-(3-trifluorométhoxy)phényl biguanide et ses utilisations Download PDF

Info

Publication number
WO2023278300A1
WO2023278300A1 PCT/US2022/035084 US2022035084W WO2023278300A1 WO 2023278300 A1 WO2023278300 A1 WO 2023278300A1 US 2022035084 W US2022035084 W US 2022035084W WO 2023278300 A1 WO2023278300 A1 WO 2023278300A1
Authority
WO
WIPO (PCT)
Prior art keywords
hours
cancer
dosage form
solid dosage
administration
Prior art date
Application number
PCT/US2022/035084
Other languages
English (en)
Other versions
WO2023278300A8 (fr
Inventor
Dean WELSCH
Thomas E. Richardson
Original Assignee
ImmunoMet Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImmunoMet Therapeutics, Inc. filed Critical ImmunoMet Therapeutics, Inc.
Publication of WO2023278300A1 publication Critical patent/WO2023278300A1/fr
Publication of WO2023278300A8 publication Critical patent/WO2023278300A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material

Abstract

L'invention concerne des formes posologiques solides de N-1-pyrrolidine-N-5-(3-trifluorométhoxy)phényl biguanide, ou un sel pharmaceutiquement acceptable de celui-ci, la forme posologique solide comprenant un revêtement entérique, et leurs utilisations.
PCT/US2022/035084 2021-06-28 2022-06-27 Forme posologique solide de n-1-pyrrolidine-n-5-(3-trifluorométhoxy)phényl biguanide et ses utilisations WO2023278300A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163215706P 2021-06-28 2021-06-28
US63/215,706 2021-06-28
US202263268103P 2022-02-16 2022-02-16
US63/268,103 2022-02-16

Publications (2)

Publication Number Publication Date
WO2023278300A1 true WO2023278300A1 (fr) 2023-01-05
WO2023278300A8 WO2023278300A8 (fr) 2023-02-09

Family

ID=84691523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/035084 WO2023278300A1 (fr) 2021-06-28 2022-06-27 Forme posologique solide de n-1-pyrrolidine-n-5-(3-trifluorométhoxy)phényl biguanide et ses utilisations

Country Status (2)

Country Link
US (1) US20230000820A1 (fr)
WO (1) WO2023278300A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130177604A1 (en) * 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Compositions and Methods of Treating Metabolic Disorders
US20140127299A1 (en) * 2012-11-07 2014-05-08 NaZura BioHealth, Inc. GRAS Enteric Coating Formulations and Methods of Making and Using Same
US9539238B2 (en) * 2015-05-13 2017-01-10 Immunomet Therapeutics, Inc Pharmaceutical composition comprising a biguanide derivative as an active ingredient for preventing or treating glioblastoma
US9540325B2 (en) * 2011-08-08 2017-01-10 ImmunoMet Therapeutics, Inc. N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
US20200093750A1 (en) * 2013-01-05 2020-03-26 Alain D. Baron Compositions and methods for treating metabolic disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451808B1 (en) * 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540325B2 (en) * 2011-08-08 2017-01-10 ImmunoMet Therapeutics, Inc. N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
US20130177604A1 (en) * 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Compositions and Methods of Treating Metabolic Disorders
US20140127299A1 (en) * 2012-11-07 2014-05-08 NaZura BioHealth, Inc. GRAS Enteric Coating Formulations and Methods of Making and Using Same
US20200093750A1 (en) * 2013-01-05 2020-03-26 Alain D. Baron Compositions and methods for treating metabolic disorders
US9539238B2 (en) * 2015-05-13 2017-01-10 Immunomet Therapeutics, Inc Pharmaceutical composition comprising a biguanide derivative as an active ingredient for preventing or treating glioblastoma

Also Published As

Publication number Publication date
US20230000820A1 (en) 2023-01-05
WO2023278300A8 (fr) 2023-02-09

Similar Documents

Publication Publication Date Title
US20130259906A1 (en) Pharmaceutical composition comprising one or more fumaric acid esters
US20180256530A1 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
JP6434429B2 (ja) デフェラシロクスの経口製剤
JP2008507586A (ja) ラサグリンを含む、医薬投与剤
JP5052602B2 (ja) 制御用量薬物送達システム
KR102381586B1 (ko) 메살라진의 경구용 약제학적 조성물
JP5026262B2 (ja) 経口抗菌医薬組成物
CZ454090A3 (en) Pharmaceutical preparations for preventing and/or treating myocardial heart attack or brain apoplexy of mammals
CN101972236A (zh) 一种含吡非尼酮的缓释制剂
JP2004521910A (ja) トラマドール系薬剤
CN1682719B (zh) 一种含有石杉碱甲的肠溶包衣缓释片剂及制备方法
JP7246384B2 (ja) 遅延放出デフェリプロン錠剤及びその使用法
JP6243351B2 (ja) パーキンソン病の固定投与量薬剤組合せ治療
CN114209667A (zh) 包含丙戊酸的延迟释放药物制剂和其用途
US20230000820A1 (en) Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof
US20210290557A1 (en) Multi-particulate pharmaceutical composition, immediate release pellets, sustained release pellets, enteric release pellets and use thereof
KR102612984B1 (ko) 에스오메프라졸 또는 이의 약학적으로 허용 가능한 염을 포함하고 이중방출 프로파일을 갖는 약학적 조성물
WO2000078307A1 (fr) Preparation pharmaceutique a administration orale ayant une action therapeutique sur les troubles gastro-intestinaux, contenant de la ranitidine enrobee, du sous-citrate de bismuth et du sucralfate
US20190374474A1 (en) Pharmaceutical compositions and methods for weight loss
CZ20004698A3 (cs) Lék pro podporu skončení nebo omezení kouření nebo prevence recidivy kouření
US20130078287A1 (en) Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist
US20230330076A1 (en) Controlled release formulations of flavoxate and process for preparation thereof
WO2019240755A1 (fr) Compositions pharmaceutiques et procédés pour une perte pondérale
KR20180002437A (ko) 독실아민 및 피리독신을 포함하는 약제학적 복합 제제

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22833978

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE